What is Takhzyro?
TAKHZYRO is the #1 prescribed HAE
preventive treatment.*
*Based on total patients on HAE preventive treatments according to US
third-party industry healthcare data.
In a 6.5-month clinical study of 125 people with HAE 12 years of age and older, people taking TAKHZYRO 300 mg every 2 weeks had
3,250+ PEOPLE IN THE
U.S. PRESCRIBED†
after talking to their doctors
FEWER ATTACKS OR
ZERO ATTACKS IN
2 CLINICAL STUDIES
A 6.5-month clinical trial
and a 2.5-year open-label
extension study‡
≤1 MINUTE
TO INJECT
for most people in the
clinical studies§
†Based on product shipments since 2018. ‡The 6.5-month clinical study included 125 people diagnosed with HAE aged 12 years and older. The main goal of the study was to evaluate the ability of TAKHZYRO 300 mg every 2 weeks to reduce the frequency of HAE attacks. On average, people had 87% fewer attacks compared to placebo. 44% of people had zero attacks for the entire 6.5-month study compared to 2% of those taking placebo. The 2.5-year open-label extension study included 212 people diagnosed with HAE aged 12 years and older. The main goal of this study was to evaluate the long-term safety of TAKHZYRO 300 mg every 2 weeks. Patients knew they were receiving TAKHZYRO, which could have influenced the study results. In this study, people taking TAKHZYRO for an average of 2.5 years had similar results to those in the 6.5-month clinical study. On average, people had 87% fewer attacks compared with baseline. ~69% of people had zero attacks for up to a year. §For people 12 years of age and older taking TAKHZYRO. In clinical studies, the majority of patients self-administered TAKHZYRO over 10 to 60 seconds. These injection times are based on vial administration.
The recommended dose is 300 mg every 2 weeks for people starting on TAKHZYRO.
If you have zero attacks for more than 6 months, your doctor may consider prescribing TAKHZYRO 300 mg once every 4 weeks.
View Transcript
SCOTT: Effective prevention means not just reducing the amount of HAE attacks I have, but also having to take TAKHZYRO just once every two weeks.
DENNIS: Effective prevention means it has the potential to reduce the frequency of my HAE attacks. With TAKHZYRO, not only am I having fewer attacks, but they're also less severe.
SORAYA: I used to have three HAE attacks a week and felt like I was spending half my life in the hospital. Now, I'm having periods of as long as two months with zero attacks, thanks to TAKHZYRO. Which is great because for me, even one attack is too many.
KELLY: Before preventive treatment, I felt like I could have an HAE attack at any moment. But in the last 12 months, I've only had one attack. That's incredible. I feel like now that I'm having fewer attacks, I've reached a new normal.
JACK: Years ago, HAE attacks forced me to quit my job. Reducing the frequency of my HAE attacks has helped me to focus on my career as a nurse.
ANDREW: Before I started preventive treatment, if I had an HAE attack, I would basically try my best to manage it in the moment. I would treat the swell reactively with my on-demand medicine and just wait for it to go down. Now that I'm taking TAKHZYRO, I know there's a way to help prevent my HAE attacks.
NARRATOR: TAKHZYRO (lanadelumab) is a prescription medicine used to prevent attacks of hereditary angioedema, HAE, in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age. TAKHZYRO may cause serious side effects including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, fast heartbeat, faintness, rash, and/or hives.
NARRATOR: The most common side effects seen with TAKHZYRO were injection site reactions: pain, redness, and bruising; upper respiratory infection and headache. These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-1088. TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.
NARRATOR: Talk to your healthcare provider about TAKHZYRO, the only preventive HAE treatment you take as a subcutaneous injection just once every two weeks.
Are you ready to reimagine your life with fewer HAE attacks?
TAKHZYRO was evaluated in 3 clinical studies: a 6.5-month study and a 2.5 year open-label extension study in adolescents and adults, and a 12-month pediatric study.
see study results
Want to learn more?
Attending a TAKHZYRO+YOU event is a great way to learn and discover more about TAKHZYRO. You'll hear from healthcare professionals as well as people taking TAKHZYRO.
FIND EVENTS